New Market Report: Puerto Rico Pharmaceuticals & Healthcare Report Q2 2015

A downward trend is being witnessed in the Puerto Rican p harmaceutical and h ealthcare markets, as key players are being forced to cut back on manufacturing efforts. However ,this short-term hindrance will not impact long - term growth. Furthermore, in facing nationwide economic troubles, members of the pharmaceutical and healthcare industry may be key players in growth recovery efforts.

Headline Expenditure Projections

* Pharmaceuticals: USD3.02bn in 2014 to USD3.00bn in 2015; -0.8%. Forecast down compared with Q 1 1 5 .
* Healthcare: USD8.02bn in 2014 to USD8.32bn in 2015; +3.7%. Forecast slightly down compared with Q 1 1 5 .

Full Report Details at
- http://www.fastmr.com/prod/951963_puerto_rico_pharmaceuticals_healthcare_report_q2.aspx?afid=301

Risk/Reward Index

Puerto Rico is the third most attractive pharmaceutical market in the Americas region, behind the US and Canada. Puerto Rico's Pharmaceutical Risk/Reward Index score of 63.8 out of 100 is unchanged from Q115. However, its position is threatened by improvements in Brazil, Mexico, Argentina and Colombia, given their lower operating costs and improving business environments.

Key Trends And Developments

* It was announced in January 2015 that Novartis will be closing its manufacturing facility in Humacao, Puerto Rico, as part of a major overhaul of its business. Company representatives disclosed that the shutdown will conclude in early 2019, with about 270 job losses. Novartis will transfer some manufacturing and packaging operations to its manufacturing plant in Lincoln, Nebraska, and other companies such as Eli Lily.
* In December 2014, US-based Romark Laboratories said it will construct a USD110mn facility in Puerto Rico. Construction will start in January 2015 and employ 200 people within three years.
* In December 2014, Sanofi's animal health company Merial announced it would buy a Merck manufacturing plant in Puerto Rico that was being closed and retain its 200 employees. The plant is expected to manufacture and package Heartgard and Heartgard Plus products.

BMI Economic View: The Puerto...

The Puerto Rico Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Puerto Rico Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Puerto Rico pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's pharmaceutical and healthcare market forecasts for Puerto Rico, to test other views - a key input for successful budgeting and strategic business planning in the Puerto Rican pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Nigeria Pharmaceuticals & Healthcare Report Q2 2015
- Mexico Pharmaceuticals & Healthcare Report Q2 2015
- Thailand Pharmaceuticals & Healthcare Report Q2 2015
- Croatia Pharmaceuticals & Healthcare Report Q2 2015
- Kenya Pharmaceuticals & Healthcare Report Q2 2015